文献速递甲状腺疾病

新型抗CD40单抗Iscalimab治疗Graves甲亢的概念验证试验

A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

本开放标签II期概念验证研究纳入15例Graves病甲亢患者,给予Iscalimab 10 mg/kg静脉输注5次、共12周。结果显示7例(47%)出现临床应答及生化甲功正常,TSH受体抗体全部显著下降(平均15.3 IU/L降至4.0 IU/L,降幅66%,P<0.001),治疗相关不良事件均为轻中度。

要点

  • Iscalimab在部分Graves甲亢患者中可实现临床应答和生化甲功正常。
  • TSH受体抗体在所有患者中显著下降,降幅66%(P<0.001)。
  • 治疗相关不良事件均为轻中度,研究期间均缓解。

核心结论

  • Iscalimab在Graves甲亢患者中总体安全,并在部分患者中显示临床疗效。

研究设计与样本

  • 开放标签、多中心、II期概念验证研究,纳入15例Graves病甲亢患者。
  • 干预为Iscalimab 10 mg/kg静脉输注5次,历时12周。

主要发现

  • 7/15(47%)患者出现临床应答及生化甲功正常,且未使用抗甲状腺药物救援。
  • 2/15(13.3%)患者促甲状腺激素恢复正常。
  • 6例(40%)患者需要抗甲状腺药物救援治疗。
  • 7例应答者中4例在治疗完成后复发。
  • TSH受体抗体在所有患者中显著下降(平均15.3 IU/L vs 4.0 IU/L,降幅66%,P<0.001),4例(27%)抗体水平恢复正常。

临床怎么用

  • Iscalimab可能作为Graves甲亢的潜在靶向治疗选择,但需进一步试验验证。

局限性

  • 开放标签、单臂、样本量小(15例)的概念验证研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves disease (GD) by promoting autoreactive B-cell activation. OBJECTIVE: Evaluate efficacy and safety of a human, blocking, nondepleting anti-CD40 monoclonal antibody, iscalimab, in hyperthyroid patients with GD. DESIGN: Open-label, phase II proof-of-concept study. SETTING: Multicenter. PATIENTS: Fifteen with GD. INTERVENTION: Patients received 5 doses of iscalimab at 10 mg/kg intravenously over 12 weeks. MAIN OUTCOME MEASURES: Thyroid-related hormones and autoantibodies, plasma soluble CD40, free CD40 on B cells, soluble CXCL13, pharmacokinetics, and safety were assessed. RESULTS: The iscalimab intervention resulted in complete CD40 engagement for up to 20 weeks. A clinical response and biochemical euthyroidism was observed in 7 of 15 (47%) patients. Free and total triiodothyronine and thyroxine normalized in 7 patients who did not receive any rescue medication with antithyroid drugs (ATD), and 2/15 (13.3%) showed normal thyrotropin. Six (40%) patients required ATD. Four of 7 responders relapsed after treatment completion. Serum concentrations of thyrotropin receptor autoantibodies (TSH-R-Ab) significantly declined in all patients (mean 15.3 IU/L vs 4.0 IU/L, 66% reduction; P < 0.001) and TSH-R-Ab levels normalized in 4 (27%). Thyroperoxidase and thyroglobulin autoantibodies significantly decreased in responders. Iscalimab rapidly reduced serum CXCL13 concentrations (P < 0.001). Twelve (80.0%) patients reported at least 1 adverse event (AE). All treatment-related AE were mild or moderate and resolved by end of the study. CONCLUSION: Iscalimab was generally safe and clinically effective in a subgroup of hyperthyroid GD patients. The potential therapeutic benefit of iscalimab should be further tested.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kahaly GJ, Stan MN, Frommer L, et al. A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial. J Clin Endocrinol Metab. 2020. PMID: 31512728. doi:10.1210/clinem/dgz013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。